Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05504434
Other study ID # MEC-2022-0285
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 4, 2022
Est. completion date December 30, 2023

Study information

Verified date February 2024
Source Erasmus Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Several infectious outbreaks have been described in the literature as a result of contaminated endoscopes. These endoscopes cannot be sterilized and require an extensive cleaning process in which breaches of cleaning protocols, endoscope damage or the formation of biofilm can prevent proper disinfection. The risk of endoscopy associated infection (EAI) and colonization due to contaminated endoscopes is still considered to be low. However, it is likely that there is severe underreporting of outbreaks due to a lack of recognition or assuming an infection to be endogenous. Due to the sheer volume of upper-gastrointestinal endoscopy worldwide, even with a low risk of EAI, the number of affected patients is significant. In response, several manufacturers have turned to the production of single-use endoscopes that eliminate the risk of exogenous infections. There are single use duodenoscopes on the market that almost seem to match the performance of reusable duodenoscopes. A new single use sterile gastroscope, Ambu aScope gastro, has been developed whose performance has not been previously described in patients. This multicenter single arm consecutive case series study will test the performance of these single use gastroscopes in patients undergoing esophagogastroduodenoscopy.


Description:

Esophagogastroduodenoscopy (EGD) is an important tool in the diagnosis and treatment of upper gastrointestinal-disorders. It has broad range of indications including dysphagia, gastroesophageal reflux disease, esophageal strictures or upper gastrointestinal (GI) bleeding. It is a common procedure and is performed around 6.1 million times annually in the United States. However, performing endoscopy is not without risk and complications of EGD include perforation, bleeding, aspiration, and infection. Endoscopy associated infection (EAI) can be endogenous, due to translocation of the patient's own microbial gut flora into the bloodstream, or exogenous as a result of contaminated equipment. The latter receives increased attention as several outbreaks have been reported past decades. Endoscopes cannot be sterilized and require an extensive cleaning process in which breaches of cleaning protocols, endoscope damage or the formation of biofilm can prevent proper disinfection. Many of the published outbreaks involved contaminated duodenoscopes. However, multiple outbreaks due to a contaminated gastroscopes have also been described. The prevalence of contaminated ready-to-use gastroscopes has rarely been studied. One study reported the contamination of ready-to-use gastroscopes to be 64% post-high-level disinfection (HLD), which went down to 9% post-storage. It is probable that EAI's are underreported due to a lack of recognition of EAI's caused by sensitive microorganisms, sparse microbiological surveillance post-endoscopy or the possibly long duration between the endoscopy and the development of the infection. However, even if the risk of EAI is low, due to the large numbers of endoscopies performed worldwide the number of affected patients is significant. Single use endoscopes would completely eliminate the risk of exogenous EAI's. Already multiple single-use duodenoscopes have been brought to the market whose performance seems be comparable to reusable duodenoscopes. To address the risk of contaminated gastroscopes, Ambu is a company who produced a single-use gastroscope, the AmbuĀ® aScopeā„¢ gastro. It is a lightweight scope equipped with two LED lights for optimal illumination and a high-resolution digital camera. The aScope gastro has recently been CE-approved, but no studies about its performance in patients have been published


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 30, 2023
Est. primary completion date December 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is planned to undergo gastroscopy for any indication either outpatient or inpatient - The subject is = 18 years old Specifically for the Netherlands: - The subject is capable to understand the information required to give informed consent Exclusion Criteria: - Terminally ill patients - Patients whose condition in the opinion of the investigator would interfere with adequately assessing the study outcomes - Patients that participate in other investigational studies which would interfere with the outcomes of this study

Study Design


Intervention

Device:
Single-use gastroscope
Adults patients are treated with a single use gastroscope instead of a reusable gastroscope

Locations

Country Name City State
Netherlands Erasmus Medical Center Rotterdam Zuid Holland
Norway Oslo University Hospital - Rikshospitalet Oslo

Sponsors (3)

Lead Sponsor Collaborator
Erasmus Medical Center Ambu A/S, Maag Lever Darm Stichting

Countries where clinical trial is conducted

Netherlands,  Norway, 

References & Publications (4)

ASGE Standards of Practice Committee; Ben-Menachem T, Decker GA, Early DS, Evans J, Fanelli RD, Fisher DA, Fisher L, Fukami N, Hwang JH, Ikenberry SO, Jain R, Jue TL, Khan KM, Krinsky ML, Malpas PM, Maple JT, Sharaf RN, Dominitz JA, Cash BD. Adverse events of upper GI endoscopy. Gastrointest Endosc. 2012 Oct;76(4):707-18. doi: 10.1016/j.gie.2012.03.252. No abstract available. — View Citation

Bajolet O, Ciocan D, Vallet C, de Champs C, Vernet-Garnier V, Guillard T, Brasme L, Thiefin G, Cadiot G, Bureau-Chalot F. Gastroscopy-associated transmission of extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa. J Hosp Infect. 2013 Apr;83(4):341-3. doi: 10.1016/j.jhin.2012.10.016. Epub 2013 Jan 20. — View Citation

McCafferty CE, Aghajani MJ, Abi-Hanna D, Gosbell IB, Jensen SO. An update on gastrointestinal endoscopy-associated infections and their contributing factors. Ann Clin Microbiol Antimicrob. 2018 Oct 10;17(1):36. doi: 10.1186/s12941-018-0289-2. — View Citation

Ofstead CL, Buro BL, Hopkins KM, Eiland JE, Wetzler HP, Lichtenstein DR. Duodenoscope-associated infection prevention: A call for evidence-based decision making. Endosc Int Open. 2020 Dec;8(12):E1769-E1781. doi: 10.1055/a-1264-7173. Epub 2020 Nov 17. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Performance of a single use gastroscope, Ambu aScope gastro, for esophagogastroduodenoscopy Is the endoscopist able to complete the desired diagnostics/therapeutics during the EGD 4 months
Secondary Qualitative assessment of the single-use gastroscope Qualitative assessment of the single-use gastroscope, Ambu aScope gastro, compared to the experience only having used re-usable devices by means of a questionnaire answered by the endoscopist post-EGD. The following characteristics will be rated on a 5 point Likert scale ranging from "much worse" to "much better":
Ease of intubation
Ease of intubating duodenum
Completeness of inspection of the upper digestive track
Image quality
Handling
Lighting
Color reproduction
Air delivery
Therapeutics
4 months
Secondary Complications of EGD Complications of EGD including pain post-EGD, bleeding, perforation, and 30-day post-gastroscopy infection rates 4 months
Secondary Incidence of switching to reusable endoscope 4 months
Secondary Time to complete procedure 4 months
See also
  Status Clinical Trial Phase
Completed NCT01350050 - Topical Pharyngeal Anesthesia With Articaine for Gastroscopy Phase 4
Completed NCT04292496 - Anastomotic Leak Testing in Gastrectomy N/A
Completed NCT05219136 - Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol N/A
Completed NCT04150237 - Using Simulation to Ensure Basic Competence in Gastroscopy
Completed NCT05012527 - Retrospective Review of Gastrointestinal System Endoscopy Procedures
Recruiting NCT05965921 - Real-life Prospective Evaluation of Computer-aided Detection (CAD) of Barrett's Neoplasia
Completed NCT02576340 - Spasmolytic in Upper Gastrointestinal Endoscopy Phase 4
Completed NCT01154530 - Chlorhexidine Mouthwash and Bacterial Contamination During Endoscopy N/A
Completed NCT05773807 - Effect of Bispectral Index Monitoring (BIS) on Body Movement of Outpatients Undergoing Gastroscopy N/A
Completed NCT04247399 - Simulation-assisted Teaching in Learning Gastroscopy N/A
Not yet recruiting NCT05693298 - High Flow Nasal Cannula in Patients Undergoing Gastroscopy N/A
Completed NCT04682821 - The Research of AI Assistant Gastroscope Training N/A
Completed NCT01151228 - Bedside Ultrasound Assessment of Gastric Content and Volume N/A
Recruiting NCT04641455 - Use of Mucolytic Solution Before Upper Endoscopy N/A
Not yet recruiting NCT06303037 - Effect of Esketamine on 95% Induction Dose of Remimazolam Phase 4